These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16008658)

  • 61. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 62. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines.
    Gurbuz AT; Elliott WG; Zia AA
    Eur J Cardiothorac Surg; 2005 Jan; 27(1):138-49. PubMed ID: 15621486
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta.
    Mazzon E; Guarneri C; Giacoppo S; Rifici C; Tchernev G; Polimeni G; Wollina U
    Int J Immunopathol Pharmacol; 2014; 27(4):669-74. PubMed ID: 25572749
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interferon beta-1b injection site reactions and necroses.
    Gaines AR; Varricchio F
    Mult Scler; 1998 Apr; 4(2):70-3. PubMed ID: 9599336
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Bramanti P; Sessa E; Rifici C; D'Aleo G; Floridia D; Di Bella P; Lublin F
    Neurology; 1998 Dec; 51(6):1720-3. PubMed ID: 9855531
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adherence to therapy: using an evidence-based protocol.
    Moore LA; Kaufman MD; Algozzine R; Irish N; Martin M; Posey CR
    Rehabil Nurs; 2007; 32(6):227-32. PubMed ID: 18065143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes.
    Tremlett HL; Oger J
    Mult Scler; 2004 Jun; 10(3):298-301. PubMed ID: 15222695
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis.
    Tremlett H
    Neurology; 2002 Jun; 58(12):1868. PubMed ID: 12084903
    [No Abstract]   [Full Text] [Related]  

  • 73. Morphea secondary to interferon beta1b injection: a case and review of the literature.
    Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis.
    Albani C; Albani G
    J Neurol Neurosurg Psychiatry; 1997 Apr; 62(4):418. PubMed ID: 9120466
    [No Abstract]   [Full Text] [Related]  

  • 75. Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection.
    Fruland JE; Sandermann S; Snow SN; Friedl A; Sharata HH
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):488-9. PubMed ID: 9308568
    [No Abstract]   [Full Text] [Related]  

  • 76. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 77. Focal neuropathy associated with cutaneous necrosis at the site of interferon-beta injection for multiple sclerosis.
    Créange A; Lefaucheur JP
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):395. PubMed ID: 10787312
    [No Abstract]   [Full Text] [Related]  

  • 78. [Extensive cutaneous-subcutaneous infiltration as a side-effect of interferon-beta injection].
    Ziegler VR; Kränke B; Soyer P; Aberer W
    Hautarzt; 1998 Apr; 49(4):310-2. PubMed ID: 9606633
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pregnancy outcomes in patients exposed to interferon beta-1b.
    Romero RS; Lünzmann C; Bugge JP
    J Neurol Neurosurg Psychiatry; 2015 May; 86(5):587-9. PubMed ID: 25185209
    [No Abstract]   [Full Text] [Related]  

  • 80. Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment.
    Mozafari N; Saffaei A; Alizadeh M; Shabani M
    J Cosmet Dermatol; 2020 Apr; 19(4):951-953. PubMed ID: 31436377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.